HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia in 40 cases

Xing-bing Wang,Hui-lan Liu,Liang-quan Geng,Xin Liu,Hui-zhi Yang,Yong-sheng Han,Bao-tin Tang,Wei-bo Zhu,Zu-yi Wang,Zi-min Sun

DOI: https://doi.org/10.3969/j.issn.1673-8225.2009.14.002

2009-01-01

Abstract:Background: Allogeneic hematopoietic stem celltransplantation (allo-HSCT) is the only method for treating chronic myelocytic leukemia (CML) presently. With development of transplantation technology, young patients with identical HLA donors may have a little short-term risk to obtain a long-term curative effect for treating disease. Objective: To retrospectively analyze the clinical outcome of HLA matched sibling donor allo-HSCT for CML. Design: Retrospective case analysis. Participants: A total of 40 CML patients (2)9 males and 11 females) undergoing allo-HSCT, averagely aged 35 years, at the Department of Hematology, Anhui Provincial Hospital,were enrolled from February 2002 to December 2007. 30 patients were in chronic phase, 5 in the accelerated phase and 5 in blast phase. Donors were identical to HLA6/6 site. Methods: Grouping was done according to transplantation method. 3 cases received allogeneic bone marrow transplantation. 8 cases received allogeneic peripheral blood stem cell transplantation. 29 cases received peripheral blood stem cell transplantation combined with bone marrow transplantation (combination group). Conditioning regimens were BuCy2 protocol or total body irradiation + cyclophosphamide + fludarabine protocol. Mycophenolate mofetile and cyclosporin A were used for graft-versus-host disease (GVHD) prophylaxis. The average follow up was 28 months. Main Outcome Measures: The following parameters were measured: recovery of hematopoietic function, transplantation-related complication, relapse, turnover, and long-term survival. Results: All 40 patients were successfully engrafted. Among them, acute GVHD occurred in 12 patients (30%), grade I in 5 cases (13%), grade II in 6 cases (15%), grade III in 1 case (3%). Chronic GVHD was in 15 among 39 patients (39%). The incidence rate of chronic GVHD was significantly higher in allogeneic peripheral blood stem cell transplantation group compared with combination group (P < 0.05). Of 40 patients, chronic hemorhagic cystitis (grade II to III) occurred in 11 patients. Evidence of acute hemorhagic cystitis and hepatic veno-occlusive disease could not be discovered in 40 patients. The overall survival was 80%, of which the survival rate was 87% in patients receiving transplantation in chronic phase, 20% in blast phase. 5 patients in accelerated phase, who achieved chronic phase twice treated with imatinib, were still alive. 8 patients died, of which 2 cases died from leukemia relapse, 5 from transplantation-related complications and 1 from suicide. Conclusion: HLA matched sibling donor allogeneic HSCT is a curative form in treatment for patients with CML, especially in chronic period.